



2 December 2013

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

EXPIRY OF UNLISTED OPTIONS

The Company advises that 25,000 unlisted options (CYPAO) lapsed on 30 November 2013.

The total number of options remaining on issue is as follows:

Code	Expiry Date	Exercise Price	Options
CYPO (Listed)	31/12/14	\$0.20	11,164,701
CYPAI	27/09/18	\$0.40	5,000,000
CYPAK	09/09/16	\$0.40	500,000
			16,664,701

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse".

Peter Webse
Company Secretary

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.